Home › Markets › Health Care › KURA

Kura Oncology Inc. (KURA)

KURA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$9.83
-5.43% on the day
Market cap
$874.5M
Small cap
Revenue · 2025
$67.5M
+25.2% on 2024
Net income · 2025
-$278.7M
-412.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerKURA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001422143
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$67.5M
Net income-$278.7M
Operating income-$303.6M
Net margin-412.9%
Operating margin-449.9%
Revenue growth+25.2%
Cash$149.1M
Total assets$738.4M
P/E (computed)Net income was not positive
P/S (computed)13.0×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32024-02-15
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-08-12
Latest current report8-K2026-09-09
Latest proxyDEFA14A2026-05-26

Source: SEC EDGAR submissions feed, 805 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.7%
1 month-14.7%
3 months-11.5%
Year to date-7.3%
1 year-3.0%
From 52-week high-29.1%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RIGLRigel Pharmaceuticals Inc.$47.14-3.42%$880.6M
ANROAlto Neuroscience Inc.$22.09-8.53%$866.9M
MLTXMoonLake Immunotherapeutics$10.41-2.53%$886.0M
SPTXSeaport Therapeutics Inc.$16.08-6.24%$860.8M
CYRXCryoPort Inc.$16.95+0.65%$858.5M
JBIOJade Biosciences Inc.$13.42-4.14%$853.5M
ALMSAlumis Inc.$6.56-7.08%$849.1M
AKTSAktis Oncology Inc.$16.64-4.04%$925.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier